申请人:Astra AB
公开号:US05594000A1
公开(公告)日:1997-01-14
Compounds of general formula I, ##STR1## wherein R.sup.1 represents hydrogen or alkyl C.sub.1-3, R.sup.2 represents hydrogen, alkyl C.sub.1-6, alkenyl C.sub.3-6 or alkynyl C.sub.3-6, n and m are integers from 1 to 3, provided that n+m=4, and one of X and Y represents CH.sub.2 and the other represents CHR.sup.3, C=CHR.sup.4 or C=NR.sup.5, in which R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.12, R.sup.13, R.sup.14, R.sup.15, R.sup.16 and R.sup.17 are as defined in the specification, and their salts are useful as pharmaceuticals, in particular as central muscarinic acetylcholine receptors. The compounds are therefore useful in the treatment of diseases such as presenile and senile dementia, Huntington's chorea, tardive dyskinesia, hyperkinesia, mania and Tourette Syndrome, and also as analgesic agents for use in the treatment of severe painful conditions such as rheumatism, arthritis, and terminal illness.
通式I的化合物,其中R.sup.1代表氢或烷基C.sub.1-3,R.sup.2代表氢,烷基C.sub.1-6,烯基C.sub.3-6或炔基C.sub.3-6,n和m是1至3的整数,且n+m=4,其中X和Y中的一个代表CH.sub.2,另一个代表CHR.sup.3,C=CHR.sup.4或C=NR.sup.5,在其中R.sup.3,R.sup.4,R.sup.5,R.sup.6,R.sup.7,R.sup.8,R.sup.9,R.sup.10,R.sup.11,R.sup.12,R.sup.13,R.sup.14,R.sup.15,R.sup.16和R.sup.17如规范中所定义,并且它们的盐是作为药物有用的,特别是作为中枢胆碱能乙酰胆碱受体。因此,这些化合物在治疗老年性痴呆症、亨廷顿舞蹈症、迟发性运动障碍、高动力症、躁狂症和杜雷特综合征等疾病方面有用,也可作为镇痛剂用于治疗类风湿、关节炎和晚期疾病等严重疼痛的情况。